Developing a new cell therapy to treat acute radiation syndrome
Official title: DEVELOPMENT OF PLX-R18 CELL THERAPY AS A COUNTERMEASURE FOR HEMATOPOIETIC ACUTE RADIATION SYNDROME
Funded at Pluristem, LTD · NIH-11105744 · Data updated 2026-11-12
This study is testing a new treatment using special cells from human placenta to help people recover from the harmful effects of radiation exposure, even if it's been a while since the exposure, and it aims to eventually get approval for use in hospitals.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pluristem, LTD NIH-funded |
| Lab location | 1 site (Haifa, ISRAEL) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,416,470 |
| NIH project number | 75N93023C00012-P00002-9999-1 |
| Project ID | NIH-11105744 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have been exposed to high levels of radiation and are at risk of developing acute radiation syndrome.
✕Less likely to help
Patients who have not been exposed to radiation or who are not at risk for acute radiation syndrome may not benefit from this research.
What this research studies
This research focuses on creating a novel cell therapy using human placenta-derived stromal cells, known as PLX-R18, to help mitigate the effects of acute radiation syndrome (H-ARS). The approach involves extensive laboratory studies to characterize these cells and assess their effectiveness in animal models after radiation exposure. The therapy aims to be administered even after significant delays post-exposure, potentially improving outcomes for those affected by radiation. The research will also include steps to seek FDA approval for this new treatment.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for individuals suffering from acute radiation syndrome, potentially improving survival and recovery rates.
How similar studies have gone: While this approach is innovative, similar research has shown promise in using cell therapies for various conditions, indicating potential for success in this novel application.
Where this research is happening
-
Pluristem, LTD
Haifa, Israel Active
Researchers
- Principal investigator: Franco-Yehuda, Chen — Pluristem, LTD
- Study coordinator: Franco-Yehuda, Chen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.